Joshua Boger

Dr. Joshua Boger founded Vertex Pharmaceuticals in 1989 with a revolutionary vision to apply the principles of structure-based drug design to discover novel therapeutics. His defining moment was the decision to bet the company's entire existence on the hypothesis that small molecules could correct the function of the misfolded CFTR protein, a scientific wager supported by the Cystic Fibrosis Foundation that ultimately resulted in the development of Kalydeco and saved the company from bankruptcy.

Dr. Joshua Boger is an American scientist and entrepreneur who founded Vertex Pharmaceuticals in 1989 and served as its CEO until 1999. He played a pivotal role in the company's early survival, navigating the severe cash crunch of the mid-1990s and executing the strategic pivot to cystic fibrosis that saved the company from bankruptcy. Boger's background as a research scientist at Merck gave him a unique perspective on the pharmaceutical industry, driving his focus on developing therapies for serious diseases using rational, structure-based drug design. During his tenure, he oversaw the early development of the company's HIV protease inhibitor programs and laid the foundational scientific infrastructure that would eventually lead to the discovery of the CFTR modulators. After stepping down as CEO, Boger remained active in the biotechnology community, serving on the boards of several major pharmaceutical companies and continuing to invest in early-stage life science startups. He is widely respected in the industry for his role in creating a global biopharmaceutical powerhouse and for his commitment to bringing novel, life-saving therapies to patients with limited treatment options.